These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8965298)

  • 1. Treatment and prevention of target organ damage.
    Padmavati S
    J Hum Hypertens; 1996 Feb; 10 Suppl 1():S85-7. PubMed ID: 8965298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
    Flaa A; Aksnes TA; Strand A; Kjeldsen SE
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New goals in hypertension management: target-organ protection beyond blood pressure lowering].
    Safar ME; Struijker-Boudier HA
    Drugs; 2003; 63 Spec No 1():45-7. PubMed ID: 12708882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of target organ damage caused by hypertension: therapeutic potential.
    Cohuet G; Struijker-Boudier H
    Pharmacol Ther; 2006 Jul; 111(1):81-98. PubMed ID: 16288809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship in cardiovascular reactivity to mental stress and early involvement of target organs in non-treated mild arterial hypertension. Hospitalet Study].
    Armario P; Hernández del Rey R; Torres G; Martín-Baranera M; Cruz Almendros M; Pardell H
    Med Clin (Barc); 1999 Oct; 113(11):401-6. PubMed ID: 10562950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients.
    Henskens LH; van Oostenbrugge RJ; Kroon AA; Hofman PA; Lodder J; de Leeuw PW
    J Hypertens; 2009 Apr; 27(4):846-53. PubMed ID: 19300113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of antihypertensive treatment on target organs].
    Fregoso Padilla J
    Arch Cardiol Mex; 2002; 72 Suppl 1():S58-63. PubMed ID: 12001872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"].
    Tislér A
    Orv Hetil; 2003 May; 144(18 Suppl 1):898-901. PubMed ID: 12785234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension.
    Stergiou GS; Argyraki KK; Moyssakis I; Mastorantonakis SE; Achimastos AD; Karamanos VG; Roussias LG
    Am J Hypertens; 2007 Jun; 20(6):616-21. PubMed ID: 17531917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertension and the heart].
    Wachtell K; Andersen NH; Svendsen TL
    Ugeskr Laeger; 2009 Jun; 171(25):2113-6. PubMed ID: 19671394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rat chromosome 19 transfer from SHR ameliorates hypertension, salt-sensitivity, cardiovascular and renal organ damage in salt-sensitive Dahl rats.
    Wendt N; Schulz A; Siegel AK; Weiss J; Wehland M; Sietmann A; Kossmehl P; Grimm D; Stoll M; Kreutz R
    J Hypertens; 2007 Jan; 25(1):95-102. PubMed ID: 17143179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension.
    Navarro-González JF; Mora C; Muros M; Jarque A; Herrera H; García J
    J Hypertens; 2008 Nov; 26(11):2168-75. PubMed ID: 18854757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies.
    Su DF
    Curr Opin Cardiol; 2006 Sep; 21(5):486-91. PubMed ID: 16900013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.